Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mol Ther ; 32(5): 1219-1237, 2024 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-38449313

RESUMEN

Bone cancer is common and severe. Both primary (e.g., osteosarcoma, Ewing sarcoma) and secondary (e.g., metastatic) bone cancers lead to significant health problems and death. Currently, treatments such as chemotherapy, hormone therapy, and radiation therapy are used to treat bone cancer, but they often only shrink or slow tumor growth and do not eliminate cancer completely. The bone microenvironment contributes unique signals that influence cancer growth, immunogenicity, and metastasis. Traditional cancer therapies have limited effectiveness due to off-target effects and poor distribution on bones. As a result, therapies with improved specificity and efficacy for treating bone tumors are highly needed. One of the most promising strategies involves the targeted delivery of pharmaceutical agents to the site of bone cancer by introduction of bone-targeting moieties, such as bisphosphonates or oligopeptides. These moieties have high affinities to the bone hydroxyapatite matrix, a structure found exclusively in skeletal tissue, and can enhance the targeting ability and efficacy of anticancer drugs when combating bone tumors. This review focuses on the engineering of small molecules and proteins with bone-targeting moieties for the treatment of bone tumors.


Asunto(s)
Antineoplásicos , Neoplasias Óseas , Humanos , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/terapia , Antineoplásicos/uso terapéutico , Antineoplásicos/farmacología , Animales , Difosfonatos/uso terapéutico , Difosfonatos/farmacología , Difosfonatos/química , Sistemas de Liberación de Medicamentos/métodos , Osteosarcoma/tratamiento farmacológico , Osteosarcoma/patología , Sarcoma de Ewing/tratamiento farmacológico , Sarcoma de Ewing/terapia , Terapia Molecular Dirigida/métodos , Microambiente Tumoral/efectos de los fármacos
2.
EMBO Rep ; 25(2): 593-615, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38228788

RESUMEN

Many physiological osteocalcin-regulated functions are affected in adult offspring of mothers experiencing unhealthy pregnancy. Furthermore, osteocalcin signaling during gestation influences cognition and adrenal steroidogenesis in adult mice. Together these observations suggest that osteocalcin may broadly function during pregnancy to determine organismal homeostasis in adult mammals. To test this hypothesis, we analyzed in unchallenged wildtype and Osteocalcin-deficient, newborn and adult mice of various genotypes and origin maintained on different genetic backgrounds, the functions of osteocalcin in the pancreas, liver and testes and their molecular underpinnings. This analysis revealed that providing mothers are Osteocalcin-deficient, Osteocalcin haploinsufficiency in embryos hampers insulin secretion, liver gluconeogenesis, glucose homeostasis, testes steroidogenesis in adult offspring; inhibits cell proliferation in developing pancreatic islets and testes; and disrupts distinct programs of gene expression in these organs and in the brain. This study indicates that osteocalcin exerts dominant functions in most organs it influences. Furthermore, through their synergistic regulation of multiple physiological functions, osteocalcin of maternal and embryonic origins contributes to the establishment and maintenance of organismal homeostasis in newborn and adult offspring.


Asunto(s)
Glucemia , Efectos Tardíos de la Exposición Prenatal , Animales , Femenino , Humanos , Ratones , Embarazo , Glucemia/análisis , Glucemia/metabolismo , Homeostasis , Insulina/metabolismo , Secreción de Insulina , Mamíferos/metabolismo , Osteocalcina/genética , Osteocalcina/metabolismo , Efectos Tardíos de la Exposición Prenatal/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA